Coya Therapeutics Inc (COYA) - התחייבויות לטווח ארוך להון

Strategic alliances of Coya Therapeutics, Inc. (COYA) for the treatment of ALS underscore the asset's volatility. The historical long-term debt-to-equity ratio visualizes these fluctuations, where the value of 0.00 reflects this status. Risk mitigation is provided by the reliance on external financing due to the absence of current cash flows, as well as the development of breakthrough Treg therapies against Alzheimer's disease to strengthen the future pipeline.

This indicator assesses financial leverage stability by comparing liabilities with maturities exceeding one year against the market value of equity. The long-term debt-to-equity ratio captures the extent of the company's reliance on external borrowing. The calculation is based on current market capitalization, enabling real-time assessment of default risk. For Coya Therapeutics, Inc. (COYA), a low debt load is critical, as the development of T-cell therapy depends on patent purity and FDA approval. This minimizes financial pressure during the period of costly clinical trials.